Orchid Pharma Limited (ORCHPHARMA)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2 FY27 revenue grew 14% y-y to INR341 Cr; H1 revenue up 15% to INR645 Cr
- Gross margin improved ~8 ppts to 39% in Q2; H1 margin at 36%
- Q2 EBITDA rose 148% to INR52 Cr; EBITDA margin 15% vs 7% last year
- Q2 PAT INR28.6 Cr vs loss of INR0.9 Cr last year; H1 PAT INR32 Cr
- Working capital improved; operating cash flow INR118 Cr in H1 FY27
- Merger benefits expected to show cost savings by end FY27
- Cefiderocol project commissioning targeted Dec 2026; India launch Q3 FY27
- 7-ACA plant commissioning planned Mar 2027; capacity 1,000 MT/year
- EXBLIFEP royalties run rate $3-4 million annually; commercialization progressing
- No short-term margin guidance; focus on cost control and product mix
- Multiple analyst queries on U.S. licensing and fundraising; no timelines given
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ORCHPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ORCHPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Orchid Pharma Limited
Important.
The summary above is generated automatically from Orchid Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.